EchoIQ (ASX:EIQ) is an Australian healthcare technology company developing artificial intelligence software for cardiac diagnostics using echocardiography data. Its technology is designed to help identify heart conditions that may otherwise be missed during routine clinical assessment. The company has established a commercial presence in the United States, with its EchoSolv AS product cleared by the US Food and Drug Administration and a second product, EchoSolv HF, progressing through regulatory review. As of 12 August 2026, EchoIQ was trading at A$1.66, with the stock up 5.06%, or A$0.080, on the day.

What does EchoIQ do?

EchoIQ develops AI-based software designed to analyse echocardiograms and assist healthcare professionals in identifying cardiac conditions.

Its technology is focused on extracting additional clinical information from echocardiography images and associated data. The company's objective is to support earlier and more consistent identification of cardiovascular disease while integrating AI capabilities into existing clinical workflows.

The company's commercial strategy is primarily focused on the US healthcare market, where its technology is being introduced across hospital and cardiac-care networks.

EchoSolv AS and aortic stenosis detection

EchoSolv AS is EchoIQ's AI-powered product for detecting aortic stenosis, a condition involving narrowing of the aortic valve.

The product has received FDA clearance and is being deployed across US healthcare facilities. EchoIQ has reported continued growth in the number of echocardiograms processed through the platform, reflecting expansion of its commercial deployment.

The company has also developed a growing US hospital pipeline, including larger enterprise opportunities involving multiple hospitals. This provides a potential pathway for expanding adoption beyond individual healthcare facilities.

EchoSolv HF and heart-failure detection

EchoSolv HF is another product within EchoIQ's diagnostic platform. It is designed to identify indicators associated with heart failure using echocardiography data.

The company submitted a 510(k) application to the FDA in December 2025. The product has also been supported by clinical research, including validation work involving the Mayo Clinic.

The development of EchoSolv HF expands the potential applications of EchoIQ's technology beyond aortic stenosis and could allow the company to address additional cardiac-diagnostic requirements if the product receives the necessary regulatory clearance.

US hospital expansion

The United States represents the company's principal commercial market.

EchoIQ has been expanding its hospital customer base and building a pipeline of potential enterprise deployments. Its platform has processed more than 10,200 echocardiograms in a recent quarterly reporting period, representing growth in utilisation.

The company has also developed deployment-support initiatives known as VIEW and SHADOW. These programs are designed to assist healthcare organisations with integrating the AI platform into clinical workflows.

Successful integration is an important part of healthcare technology adoption because diagnostic software must operate effectively alongside existing imaging systems, clinical processes and hospital infrastructure.

Strategic relationship with Pro Medicus

EchoIQ has entered into a strategic agreement with Pro Medicus, a medical imaging technology company with an established presence in the US healthcare market.

The relationship is intended to provide EchoIQ with access to Pro Medicus's hospital network and create opportunities for broader distribution of its technology. The agreement also included a potential Investment of approximately A$20 million.

The Partnership provides EchoIQ with an additional channel for expanding its reach among US healthcare providers and medical-imaging organisations.

Data and research partnerships

EchoIQ has continued to develop relationships that support its AI technology and clinical research.

The company secured an exclusive data agreement with Advara HeartCare providing access to up to one million echocardiography studies. Access to large datasets can support development and refinement of AI algorithms while providing additional opportunities for clinical research.

EchoIQ has also maintained its relationship with the Mayo Clinic through research collaboration in areas including cardio-oncology. Clinical research partnerships can help generate evidence for the use of AI-based diagnostic technologies and support development of additional applications.

Commercial and reimbursement considerations

Healthcare technology companies depend not only on regulatory clearance but also on the ability of healthcare providers to implement and pay for their products.

EchoIQ's existing regulatory clearance for EchoSolv AS provides an established commercial pathway in the US market. The company's strategy also benefits from existing reimbursement infrastructure associated with applicable cardiac diagnostic services.

The potential availability of established reimbursement mechanisms for future products could influence the speed at which hospitals and clinicians adopt the technology. Actual reimbursement eligibility and payment levels remain subject to applicable requirements and healthcare-system arrangements.

Development opportunities

EchoIQ's platform provides several potential avenues for expansion.

The company can increase adoption of EchoSolv AS across US hospitals while continuing development of EchoSolv HF and other potential cardiac applications.

Large healthcare datasets and research collaborations could also support the development of additional algorithms and diagnostic applications.

Strategic distribution relationships such as the Pro Medicus agreement provide another avenue for expanding the company's commercial reach without requiring the entire hospital network to be developed independently.

Key challenges

EchoIQ operates in a highly regulated healthcare technology market. Regulatory clearance is required for products intended for specific clinical applications, and regulatory outcomes can influence development timelines and commercialisation.

Commercial execution is another important consideration. Expanding from an initial group of hospital customers to larger healthcare networks requires effective sales, implementation, technical support and clinical integration.

The company is also developing its Revenue base while investing in commercial expansion and product development. Maintaining sufficient financial resources to support this growth is therefore an important part of its operating strategy.

Competition within AI-assisted medical imaging is another consideration, as healthcare technology companies and established medical-imaging providers continue developing software capable of analysing diagnostic data.

What to watch next

Future regulatory developments relating to EchoSolv HF will be important for the company's product pipeline.

Quarterly operating metrics, including echocardiogram volumes, hospital deployments and enterprise opportunities, can provide insight into commercial adoption.

The progression of the Pro Medicus relationship and potential investment will also be relevant, particularly as the companies develop opportunities across US healthcare networks.

Further clinical research, data partnerships and expansion of EchoIQ's diagnostic applications could provide additional information about the company's broader technology platform.

Current share performance

As of 12 August 2026, EchoIQ was trading at A$1.66, with the stock up 5.06%, or A$0.080, on the day.

Conclusion

EchoIQ (ASX:EIQ) is developing AI-powered cardiac diagnostic technology designed to analyse echocardiography data and support the identification of cardiovascular conditions.

Its FDA-cleared EchoSolv AS product provides an established commercial platform, while EchoSolv HF represents an additional application under regulatory development. The company's US hospital expansion, large-scale data relationships, clinical research and strategic relationship with Pro Medicus provide several avenues for further development.

The company's future progress will depend on regulatory outcomes, hospital adoption, clinical validation, commercial execution and the continued development of its AI technology platform.